Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04917536
Other study ID # RBHP 2021 VILLATTE
Secondary ID 2021-A00400-41
Status Recruiting
Phase N/A
First received
Last updated
Start date June 21, 2021
Est. completion date June 2024

Study information

Verified date May 2021
Source University Hospital, Clermont-Ferrand
Contact Lise LACLAUTRE
Phone +33473754963
Email promo_interne_drci@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to show if there is any speed difference of functional recovery for people with humeral fracture, treated by an anterograde nail, which will be inserted through the rotator cuff (the common way) or through the rotator interval split. The patients included in this study will be randomized to one of the two groups. The recovery will be evaluated by the Constant score over time, for a year. The main hypothesis is the rotator interval split approach allows a faster functional recovery after humeral nailing, by avoiding opening the rotator cuff.


Description:

Humeral fractures are the third most common fractures over 65 years and represent 8% of all fractures. The anterograde nailing is known to be an efficient way to treat humeral upper extremity fractures and humeral diaphysis fractures. The main complications of this nailing are pain, shoulder stiffness, rotator cuff tendinitis and impingement. Studies have proven these problems can be due to the entry portal of the nail. Indeed, it is inserted through the supra-spinatus tendon, which means an opening of the rotator cuff even if it is closed at the end of the procedure. But the rotator interval split in the shoulder can allow to insert the nail through it without opening the cuff or damaging the cartilage. It is located between the anterior side of the supra-spinatus tendon and the posterior side of the long part of the biceps. The aim of the study is to compare the speed of functional recovery according to the entry portal, which are through the rotator cuff or through the rotator interval split, in humeral fractures treated by anterograde nailing. The cutaneo-muscular approach will be the same in both groups, namely a trans-deltoid approach. People will be included in the study after an enlightened and signed consent, afterward they will be randomized to one of the two groups. To evaluate the primary outcome, the Constant Score will be used to measure the kinetic of the recovery. The secondary outcomes are residual pain (measured by the VAS an evaluation of complications and a radiological review (two different reviewers) to follow the healing and search any side effects, the sick leave and rehabilitation durations. The patients need to be available for a one-year follow-up. Each assessment will be checked at 21 and 45 days, and at 3, 6 and 12 months after the surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 2024
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Be available for a one year follow-up - Patients over 18 and under 70 years old - Humeral diaphysis fracture or humeral upper extremity articular fracture (Neer 2,3 or 4), needing to be treated by anterograde nailing. - No growth plates - Patients covered by the French social security service - Patients able to give their enlightened consent and to answer the questions asked for the trial Exclusion Criteria: - Pregmant, breastfeeding or potentially pregmant woman - Existing bone disease - Polytrauma - Other fractures on the same upper limb - Pathologic fracture - Medical history of surgery on the same shoulder - Contra-indication to the surgery or the anesthesia - Infection on the operating site - Axillary nerve palsy - Deltoid dysfunction - Major disability - Refusal of participation

Study Design


Intervention

Procedure:
Humeral neailling in humeral fractures
Humeral neailling in humeral fractures

Locations

Country Name City State
France CHU de Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Speed of functional recovery Measured by the objective Constant score (absolute and weighted values), which includes an evaluation of the pain, level of daily activities, use of the hand, range of motion and strength. The collected data will allow us to draw a diagram to compare the speed of recovery. Its values are between 0 (bad) and 100 (good) Day 21
Primary Speed of functional recovery Measured by the objective Constant score (absolute and weighted values), which includes an evaluation of the pain, level of daily activities, use of the hand, range of motion and strength. The collected data will allow us to draw a diagram to compare the speed of recovery. Its values are between 0 (bad) and 100 (good) Day 45
Primary Speed of functional recovery Measured by the objective Constant score (absolute and weighted values), which includes an evaluation of the pain, level of daily activities, use of the hand, range of motion and strength. The collected data will allow us to draw a diagram to compare the speed of recovery. Its values are between 0 (bad) and 100 (good) Month 3
Primary Speed of functional recovery Measured by the objective Constant score (absolute and weighted values), which includes an evaluation of the pain, level of daily activities, use of the hand, range of motion and strength. The collected data will allow us to draw a diagram to compare the speed of recovery. Its values are between 0 (bad) and 100 (good) Month 6
Primary Speed of functional recovery Measured by the objective Constant score (absolute and weighted values), which includes an evaluation of the pain, level of daily activities, use of the hand, range of motion and strength. The collected data will allow us to draw a diagram to compare the speed of recovery. Its values are between 0 (bad) and 100 (good) Month 12
Secondary Quick Dash subjective test showing any difficulties in the daily living activities, relationships, and evaluating the pain and tingling; all of these items are based on the week before the assessment. It ranges from 0 to 100 more the value is better brought up is the score. Day 21
Secondary Quick Dash subjective test showing any difficulties in the daily living activities, relationships, and evaluating the pain and tingling; all of these items are based on the week before the assessment. It ranges from 0 to 100 more the value is better brought up is the score. Day 45
Secondary Quick Dash subjective test showing any difficulties in the daily living activities, relationships, and evaluating the pain and tingling; all of these items are based on the week before the assessment. It ranges from 0 to 100 more the value is better brought up is the score. Month 3
Secondary Quick Dash subjective test showing any difficulties in the daily living activities, relationships, and evaluating the pain and tingling; all of these items are based on the week before the assessment. It ranges from 0 to 100 more the value is better brought up is the score. Month 6
Secondary Quick Dash subjective test showing any difficulties in the daily living activities, relationships, and evaluating the pain and tingling; all of these items are based on the week before the assessment. It ranges from 0 to 100 more the value is better brought up is the score. Month 12
Secondary Simple shoulder test (SST) a subjective score to evaluate what kind of activity is actually possible for the patient day 21
Secondary Simple shoulder test (SST) a subjective score to evaluate what kind of activity is actually possible for the patient day 45
Secondary Simple shoulder test (SST) a subjective score to evaluate what kind of activity is actually possible for the patient Month 3
Secondary Simple shoulder test (SST) a subjective score to evaluate what kind of activity is actually possible for the patient Month 6
Secondary Simple shoulder test (SST) a subjective score to evaluate what kind of activity is actually possible for the patient Month 12
Secondary Intensity of Pain Visual analog scale (VAS) : the pain is quantified by a number from 0 (no pain) to 10 (the worst pain ever known) Day 21
Secondary Intensity of Pain Visual analog scale (VAS) : the pain is quantified by a number from 0 (no pain) to 10 (the worst pain ever known) Day 45
Secondary Intensity of Pain Visual analog scale (VAS) : the pain is quantified by a number from 0 (no pain) to 10 (the worst pain ever known) Month 3
Secondary Intensity of Pain Visual analog scale (VAS) : the pain is quantified by a number from 0 (no pain) to 10 (the worst pain ever known) Month 6
Secondary Intensity of Pain Visual analog scale (VAS) : the pain is quantified by a number from 0 (no pain) to 10 (the worst pain ever known) Month 12
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams day 0
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams day 21
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams day 45
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams Month 3
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams Month 6
Secondary Complications assessment Searching any early or late complications, such as neurological or vascular problems, haematoma, infection, dislocation, with a clinical exam or other possible paraclinical exams Month 12
Secondary Duration of the sick leave The patient is asked when he has returned to his professional activity day 21
Secondary Duration of the sick leave The patient is asked when he has returned to his professional activity day 45
Secondary Duration of the sick leave The patient is asked when he has returned to his professional activity Month 3
Secondary Duration of the sick leave The patient is asked when he has returned to his professional activity Month 6
Secondary Duration of the sick leave The patient is asked when he has returned to his professional activity Month 12
Secondary Duration of the rehabilitation The patient is asked about the length of the physiotherapy. day 21
Secondary Duration of the rehabilitation The patient is asked about the length of the physiotherapy. day 45
Secondary Duration of the rehabilitation The patient is asked about the length of the physiotherapy. month 3
Secondary Duration of the rehabilitation The patient is asked about the length of the physiotherapy. month 6
Secondary Duration of the rehabilitation The patient is asked about the length of the physiotherapy. month 12
Secondary Surgery datas any or no transfusion of blood cells during the surgery and immediately after (Day 0)
Secondary Surgery datas time to perform the surgery collected from the operating file in minutes during the surgery (Day 0)
Secondary haemoglobin levels haemoglobin levels in g/dl during the surgery and immediately after (Day 0)
Secondary Radiological evolution consolidation or not Day 45
Secondary Radiological evolution consolidation or not Month 3
Secondary Radiological evolution consolidation or not Month 6
Secondary Radiological evolution consolidation or not Month 12
See also
  Status Clinical Trial Phase
Terminated NCT01116349 - Conservative Treatment Versus the Surgical Treatment of Diaphyseal Fractures of Humerus N/A